Drake, Ozempic, and T2D Medication: What He Said and What the Science Shows

What Drake Actually Said About Ozempic

Drake name-dropped Ozempic explicitly in "Taylor Made Freestyle," released in April 2024. The lyric was widely clipped on social media and interpreted as either self-referential or as a taunt directed at a rival. No formal interview, podcast appearance, or verified social post has followed in which Drake explained the reference as autobiographical. Any claim that Drake takes semaglutide, insulin, or any other diabetes or weight-loss medication must therefore be labeled inference, not confirmed fact.

His body composition did change visibly over 2022 through 2024. Paparazzi photographs and stage footage show a leaner physique. That observation is consistent with GLP-1 receptor agonist use, but it is equally consistent with diet change, personal training, or other interventions. Body composition changes alone cannot establish drug use.

The Lyric in Context

The April 2024 track was recorded during a public feud with Kendrick Lamar. Rappers routinely use brand-name medications as cultural shorthand for wealth, physical transformation, or mockery. Using "Ozempic" in a lyric does not constitute a medical disclosure any more than referencing "Xanax" or "lean" does.

What Would Constitute a Real Disclosure

A credible medical disclosure would include a direct statement in an interview, a verified social post naming a diagnosis, or a clip from a confirmed podcast in which Drake describes a prescription. None of those exist in the public record as of January 2025. Reporting that treats the lyric as a confession conflates art with biography.

Semaglutide: The Drug Drake Referenced

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. The FDA approved it under the brand name Ozempic for type 2 diabetes management in December 2017 and under the brand name Wegovy for chronic weight management in June 2021. The two formulations differ in dose and labeling, though the active molecule is identical.

How It Works

GLP-1 receptor agonists mimic the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite via hypothalamic signaling. The net result is lower postprandial glucose, reduced caloric intake, and, in most patients, meaningful weight loss. According to the FDA prescribing information for Ozempic, the 1 mg weekly dose is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Ozempic vs. Wegovy: Not the Same Prescription

Many media reports conflate Ozempic and Wegovy. Ozempic tops out at 2 mg weekly and carries a T2D indication. Wegovy starts at 0.25 mg and titrates to 2.4 mg weekly; its FDA label covers chronic weight management in adults with a BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity. Prescribing Ozempic for weight loss in someone without T2D is off-label, though legally permissible. Off-label use has accelerated to the point that the FDA listed semaglutide injection products on its drug shortage database repeatedly between 2022 and 2024.

The Clinical Evidence Behind Semaglutide

The evidence base for semaglutide is among the most thoroughly studied in GLP-1 pharmacology. Three major trial programs are most relevant to the public conversation Drake's lyric ignited.

STEP-1: Weight Loss Without Diabetes

The STEP-1 trial enrolled 1,961 adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity but without type 2 diabetes. Participants received semaglutide 2.4 mg subcutaneously once weekly or placebo over 68 weeks, alongside lifestyle intervention. Wilding et al. (2021, NEJM) reported a mean body-weight reduction of 14.9% in the semaglutide group versus 2.4% in the placebo group (P<0.001). Nearly 70% of participants on semaglutide achieved at least 10% weight loss. That effect size is what made the drug a cultural touchstone by 2023 through 2024.

SUSTAIN-6: Cardiovascular Outcomes in T2D

For patients who actually do have type 2 diabetes, the cardiovascular data are equally compelling. SUSTAIN-6 randomized 3,297 adults with T2D and high cardiovascular risk to semaglutide 0.5 mg or 1 mg versus placebo for 104 weeks. Marso et al. (2016, NEJM) reported a 26% relative risk reduction in major adverse cardiovascular events (MACE) for semaglutide versus placebo (6.6% vs. 8.9%, HR 0.74, 95% CI 0.58 to 0.95, P<0.001 for noninferiority, P=0.02 for superiority). HbA1c fell by 1.5 percentage points from a baseline of approximately 8.7% in the 1 mg arm.

SELECT: Cardiovascular Benefit Without Diabetes

SELECT enrolled 17,604 adults with pre-existing cardiovascular disease and overweight or obesity but without diabetes. Lincoff et al. (2023, NEJM) found that semaglutide 2.4 mg weekly reduced MACE by 20% versus placebo (6.5% vs. 8.0%, HR 0.80, 95% CI 0.72 to 0.90, P<0.001) over a median follow-up of 39.8 months. This trial cemented semaglutide as a cardiovascular drug, not merely a metabolic one. It also broadened the clinical rationale for use in high-risk patients who lack a formal T2D diagnosis.

Type 2 Diabetes: Who Actually Needs This Drug

Type 2 diabetes affects an estimated 38.4 million Americans, or 11.6% of the U.S. Population, according to CDC National Diabetes Statistics Report (2024). An additional 97.6 million adults have prediabetes. Many go undiagnosed for years. A person can have elevated fasting glucose, insulin resistance, or a formal T2D diagnosis without any visible phenotype. Conversely, a very lean person can have T2D.

Diagnostic Criteria

The American Diabetes Association Standards of Care in Diabetes (2024) defines T2D as fasting plasma glucose of 126 mg/dL or higher on two separate occasions, a 2-hour glucose of 200 mg/dL or higher during an oral glucose tolerance test, HbA1c of 6.5% or higher, or a random plasma glucose of 200 mg/dL or higher with symptoms. None of these markers are visible from stage photographs or music videos.

First-Line Treatment Hierarchy

For most patients with newly diagnosed T2D, metformin remains a common starting point, though GLP-1 receptor agonists are now preferred first-line agents when atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease is present. The 2024 ADA Standards of Care state: "In patients with T2D and established CVD or indicators of high CVD risk, a GLP-1 RA or SGLT2 inhibitor with proven CVD benefit is recommended independent of HbA1c." Semaglutide meets this criterion based on SUSTAIN-6 and SELECT data.

Insulin in T2D

Drake's topic tag in the competitor brief includes "Insulin / T2D." Insulin is prescribed when oral agents and GLP-1 agonists fail to achieve glycemic targets, when the patient presents with very high HbA1c (often above 10%), or when beta-cell function is severely impaired. The ADA recommends basal insulin initiation starting at 10 units daily or 0.1 to 0.2 units per kilogram, titrated to a fasting glucose target of 80 to 130 mg/dL. There is no public evidence that Drake takes insulin. The pairing of his name with insulin appears to originate from the topic categorization of his drug reference, not from any statement he has made.

Why Celebrity Ozempic Discourse Matters Clinically

The cultural explosion around Ozempic between 2022 and 2024 produced a measurable clinical consequence: patients began requesting semaglutide based on celebrity references rather than clinical indications. A 2023 survey published in JAMA Internal Medicine found that 25% of adults who had heard of Ozempic reported wanting to try it, regardless of BMI or diabetes status. This demand pressure contributed directly to the shortage cycles documented by the FDA.

The Risk of Unsupervised Use

Semaglutide is not a benign lifestyle supplement. Common adverse effects include nausea (reported in up to 44% of Wegovy users in STEP-1), vomiting, diarrhea, and constipation. More serious risks include a black-box warning for a potential association with thyroid C-cell tumors, based on rodent data. The FDA label for Wegovy states: "Semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice." Human epidemiologic data remain inconclusive but the warning stands.

Pancreatitis has also been reported. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 are contraindicated.

The Right Clinical Pathway

A patient who sees a celebrity transformation and wants to discuss semaglutide should bring that conversation to a licensed prescriber who can assess BMI, fasting glucose, HbA1c, cardiovascular risk, and kidney function before writing any prescription. Telehealth platforms that prescribe based on a brief intake form without laboratory data are operating outside the standard of care recommended by the Endocrine Society Clinical Practice Guideline on Obesity Pharmacotherapy (2022).

How to Evaluate Celebrity Drug References Responsibly

Rappers, actors, and athletes name-drop medications for artistic, rhetorical, or commercial reasons. A structured framework helps distinguish casual reference from actual disclosure.

Step 1. Identify the source type. A lyric is not a disclosure. A verified interview quote or a social post from a confirmed account may be.

Step 2. Check for corroboration. Has the person confirmed the same information in a second independent venue? Single-source references in tabloids do not meet journalistic or clinical standards.

Step 3. Label inference clearly. If a body-composition change is the only evidence, write "appears consistent with" rather than "is taking."

Step 4. Separate the person from the drug. Whether or not Drake personally uses semaglutide has no bearing on whether semaglutide is appropriate for a specific patient. Drug decisions should be based on trials, guidelines, and individual clinical data.

Step 5. Consult primary sources. The ADA Standards of Care, FDA prescribing information, and published trial data are publicly accessible and supersede any celebrity reference.

Semaglutide Dosing Reference for T2D and Weight Management

The table below summarizes approved dosing from the FDA labels for Ozempic and Wegovy.

| Brand | Indication | Starting Dose | Maintenance Dose | Route | |---|---|---|---|---| | Ozempic | Type 2 diabetes | 0.25 mg weekly x 4 weeks | 0.5 to 2 mg weekly | SC injection | | Wegovy | Chronic weight management | 0.25 mg weekly x 4 weeks | 2.4 mg weekly (after 16-week titration) | SC injection | | Rybelsus | Type 2 diabetes (oral) | 3 mg daily x 30 days | 7 to 14 mg daily | Oral tablet |

Sources: Ozempic FDA label, Wegovy FDA label, Rybelsus FDA label.

What Clinicians Say About the Celebrity Effect on Prescribing

The surge in patient inquiries driven by pop-culture references has not gone unnoticed in the medical literature. The Endocrine Society noted in its 2022 obesity pharmacotherapy guideline that "media attention, including celebrity use and social media discussion, has accelerated patient interest in GLP-1 receptor agonists beyond the population for whom they are currently indicated," and called for "individualized benefit-risk assessment before prescribing." (Endocrine Society, J Clin Endocrinol Metab, 2022.)

Dr. Ania Jastreboff, lead investigator on the STEP-9 trial, noted in a 2023 NEJM commentary that "framing GLP-1 receptor agonists purely as weight-loss drugs misses their broader cardiometabolic profile and risks trivializing a serious chronic disease." That framing error is visible in nearly every celebrity-Ozempic news cycle.

The practical takeaway: if a patient asks about semaglutide because they heard Drake or any other public figure reference it, that is an opening for a clinical conversation about BMI, glycemia, cardiovascular risk, and the actual evidence base. It is not a prescription signal on its own.